Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress
Rein Therapeutics (RNTX) will present a late-breaking poster at the European Respiratory Society (ERS) 2026 Congress in Barcelona, Spain, on September 8, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rein Therapeutics (RNTX) will present a late-breaking poster at the European Respiratory Society (ERS) 2026 Congress in Barcelona, Spain, on September 8, 2026.
The poster, titled “Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study”, will be presented in the session “Immunological mechanisms in pulmonary fibrosis” (Poster PA6217) from 12:30–2:00pm CEST by Philip Molyneaux, MD. The company notes that the data have been published in Nature Communications.
Details
Market move: RNTX +5.39% in the Sep 4 session. ERS 2026 poster presentation
On Sep 4, the day this news came out, RNTX closed 5.39% above the previous close. Argus tracked a peak move of +5.8% during that session. Argus tracked a trough of -3.3% from its starting point during tracking. Our momentum scanner recorded 7 alerts for this stock that day. Relative volume reached 37.8x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 4 session.
Key Figures
- Congress dates
- September 5-9, 2026
- ERS 2026 Congress
- Poster presentation date
- September 8, 2026
- ERS 2026 Congress
- Presentation time
- 12:30-2:00pm CEST
- Poster session
Historical Context
-
FDA granted Fast Track designation for LTI-03 in idiopathic pulmonary fibrosis
-
Reported second-quarter results and completed a public offering
-
Published first-in-human LTI-03 data in Nature Communications
-
RENEW began enrolling across all five planned countries
-
First United Kingdom patient randomized in the RENEW trial
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
idiopathic pulmonary fibrosis medical
dose escalation study medical
interstitial lung disease medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
AUSTIN, Texas, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that it will present a late-breaking poster at the European Respiratory Society (ERS) 2026 Congress taking place September 5-9, 2026, in Barcelona, Spain.
Poster Presentation
Title: Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study
Poster Session: Immunological mechanisms in pulmonary fibrosis
Poster Number: PA6217
Date: Tuesday, September 8, 2026
Time: 12:30-2:00pm CEST
Presenter: Philip Molyneaux, MD, Professor of Interstitial lung disease at Imperial College London and the Asthma+Lung UK Chair of Respiratory Research and Consultant in Interstitial lung disease at the Royal Brompton Hospital
Data to be presented in the poster has been published in Nature Communications and can be viewed here.
About LTI-03
LTI-03 is a first-in-class, inhaled peptide therapy derived from Caveolin-1 biology, a key regulator of fibrotic signaling. The drug is designed to inhibit lung scarring while preserving alveolar progenitor cells that are critical for tissue repair and regeneration.
Early data suggests that LTI-03 may represent a dual-acting approach: slowing fibrosis and promoting lung healing.
About the RENEW Phase 2 Trial
Rein’s RENEW trial (ClinicalTrials.gov: NCT06968845) is a randomized, placebo-controlled Phase 2 clinical study designed to evaluate the safety, tolerability, and efficacy of LTI-03 in patients with idiopathic pulmonary fibrosis.
The study is expected to enroll approximately 120 patients across the United States, United Kingdom, Australia, Poland, and Germany. Patients will be randomized to receive one of two dose levels of LTI-03 or placebo. The primary endpoint is safety, measured by the incidence of treatment-emergent adverse events through Week 24, with change from baseline in forced vital capacity (FVC) as the primary efficacy endpoint.
About Rein Therapeutics
Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein’s lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 has received both Orphan Drug and Fast Track designations in the U.S.
Investor Contact
IR@ReinTx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.